Role of bridging RT in relapsed/refractory diffuse large B-cell lymphoma undergoing CAR-T therapy: A multicenter study
Last Updated: Monday, October 28, 2024
Data from a recent retrospective trial demonstrated that among patients with relapsed/refractory DLBCL who underwent leukapheresis for CAR-T manufacturing, radiotherapy bridging is associated with a lower drop-out rate and lower CAR-T toxicity. Bridging response was overall poor, but patients receiving radiotherapy had a significant reduction in LDH levels between pre- and post-bridging (p = 0.05).
Advertisement
News & Literature Highlights
